{"id":"https://openalex.org/W2889946948","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.4529","title":"Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).","display_name":"Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).","publication_year":2018,"publication_date":"2018-05-20","ids":{"openalex":"https://openalex.org/W2889946948","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.4529","mag":"2889946948"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.15_suppl.4529","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.4529","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.4529","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044979250","display_name":"Jean H. Hoffman-Censits","orcid":"https://orcid.org/0000-0002-6970-6509","observed_orcids":["https://orcid.org/0000-0002-6970-6509"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jean H. Hoffman-Censits","raw_affiliation_strings":["John Hopkins University Sidney Kimmel Cancer Center, Baltimore, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"John Hopkins University Sidney Kimmel Cancer Center, Baltimore, MD;","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041033274","display_name":"Sumanta Kumar Pal","orcid":"https://orcid.org/0000-0002-1712-0848","observed_orcids":["https://orcid.org/0000-0002-1712-0848"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sumanta K. Pal","raw_affiliation_strings":["City of Hope, Duarte, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope, Duarte, CA;","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110830008","display_name":"Hanzhe Zheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hanzhe Zheng","raw_affiliation_strings":["Genentech, Inc., San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041518689","display_name":"Darren Tayama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Darren Tayama","raw_affiliation_strings":["Genentech, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074756323","display_name":"Joaquim Bellmunt B","orcid":"https://orcid.org/0000-0003-2328-3421","observed_orcids":["https://orcid.org/0000-0003-2328-3421","https://orcid.org/0000-0001-7569-7074"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joaquim Bellmunt","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"15_suppl","first_page":"4529","last_page":"4529"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9467999935150146,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9467999935150146,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.04989999905228615,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.9039999842643738},{"id":"https://openalex.org/keywords/metastatic-urothelial-carcinoma","display_name":"metastatic urothelial carcinoma","score":0.9829999804496765},{"id":"https://openalex.org/keywords/locally-advanced-urothelial-carcinoma","display_name":"locally advanced urothelial carcinoma","score":0.921999990940094},{"id":"https://openalex.org/keywords/expanded-access-program","display_name":"expanded access program","score":0.8159999847412109},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.8809999823570251},{"id":"https://openalex.org/keywords/renal-dysfunction","display_name":"renal dysfunction","score":0.6919999718666077},{"id":"https://openalex.org/keywords/creatinine-clearance","display_name":"creatinine clearance","score":0.8050000071525574},{"id":"https://openalex.org/keywords/histological-subtypes","display_name":"histological subtypes","score":0.7699999809265137},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.9169999957084656},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6830000281333923},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.9229999780654907}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7787392139434814},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.6765944361686707},{"id":"https://openalex.org/C2911057145","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Metastatic Urothelial Carcinoma","level":5,"score":0.6358857750892639},{"id":"https://openalex.org/C57742111","wikidata":"https://www.wikidata.org/wiki/Q7168","display_name":"Histology","level":2,"score":0.6251082420349121},{"id":"https://openalex.org/C2775832928","wikidata":"https://www.wikidata.org/wiki/Q407954","display_name":"Expanded access","level":2,"score":0.47612839937210083},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4754086136817932},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.4669184684753418},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.44489118456840515},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4084813594818115},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4073244333267212},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2282070815563202},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.2070704698562622},{"id":"https://openalex.org/C3019882237","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial carcinoma","level":4,"score":0.190720796585083},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.163936048746109},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.12901374697685242},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.07266488671302795}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.15_suppl.4529","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.4529","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.4529","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3040360976","https://openalex.org/W2889842870","https://openalex.org/W2889691772","https://openalex.org/W2601087129","https://openalex.org/W2478515289","https://openalex.org/W3032891568","https://openalex.org/W2598590627","https://openalex.org/W2788898141","https://openalex.org/W2793820634","https://openalex.org/W2491789338"],"abstract_inverted_index":{"4529":[0],"Background:":[1],"Prior":[2],"to":[3,23,149,174],"FDA":[4],"approval":[5],"of":[6,96,133,169,242],"atezo":[7,89,205,234],"(anti\u2013PD-L1)":[8],"for":[9,35,167],"platinum-treated":[10,243],"mUC":[11,20,62,244],"(and":[12],"later":[13],"cisplatin-ineligible":[14],"mUC),":[15],"a":[16,239],"US":[17],"EAP":[18,26],"granted":[19],"pts":[21,48,63,116,209,219,355,368,382,387],"access":[22],"atezo.":[24],"The":[25],"(Bellmunt":[27],"ASCO":[28],"2017)":[29],"included":[30],"special":[31,170],"populations":[32],"previously":[33],"ineligible":[34],"Ph":[36],"II":[37],"study":[38,59],"IMvigor210":[39],"(Rosenberg":[40],"Lancet":[41],"2016).":[42],"Here,":[43],"we":[44],"evaluate":[45],"outcomes":[46],"in":[47,122,131,188,197,208,218,238,375],"with":[49,204,210,220,329,356,369,378,383,388,393],"impaired":[50],"baseline":[51,253],"renal":[52,138,215],"function":[53,139,216],"or":[54,67,110,202,213,380],"variant":[55],"histology.":[56,113],"Methods:":[57],"This":[58],"(NCT02589717)":[60],"enrolled":[61],"who":[64],"progressed":[65],"during":[66],"following":[68],"platinum":[69],"and":[70,104,224,360,391],"had":[71,77,396],"ECOG":[72],"PS":[73],"\u2264":[74],"2.":[75],"Pts":[76,87],"predominant":[78],"TCC":[79,317,328],"histology":[80,159,212,318,390,395],"but":[81],"no":[82,154],"restrictions":[83],"on":[84],"CrCl":[85,109,189,221],"levels.":[86],"received":[88],"1200":[90],"mg":[91],"IV":[92],"q3w":[93],"until":[94],"loss":[95],"clinical":[97,236],"benefit.":[98],"ORR":[99],"(per":[100],"investigator),":[101],"DCR":[102],"(CR+PR+SD)":[103],"safety":[105,225],"were":[106,117,160,176,206],"assessed":[107],"by":[108,158,252],"primary":[111],"tumor":[112],"Results:":[114],"114":[115,269],"response":[118,251],"evaluable;":[119],"responses":[120,373],"occurred":[121,130,166,187,374],"most":[123],"subgroups":[124],"(Table).":[125],"All-grade":[126],"treatment-related":[127],"AEs":[128,168],"(TRAEs)":[129],"46%":[132],"214":[134],"safety-evaluable":[135],"pts.":[136,245],"In":[137],"subgroups,":[140],"TRAE":[141,155],"rates":[142],"ranged":[143],"from":[144],"35%":[145],"(CrCl":[146,151],"30-45":[147,222,289],"mL/min)":[148],"54%":[150],"45-60":[152,298],"mL/min);":[153],"rate":[156],"differences":[157],"seen":[161,207,352],"(46%":[162],"each).":[163],"Similar":[164],"trends":[165],"interest.":[171],"TRAEs":[172,185],"leading":[173],"discontinuation":[175],"uncommon":[177],"(":[178,194],"<":[179,190,195,278],"3%":[180],"across":[181,228],"subgroups).":[182,199],"Two":[183],"serious":[184],"(15%)":[186],"30":[191,279,304],"mL/min":[192,280],"subgroup":[193],"8%":[196],"other":[198],"Conclusions:":[200],"Responses":[201],"SD":[203],"mixed":[211,330],"compromised":[214],"(notably":[217],"mL/min),":[223],"was":[226,351],"comparable":[227],"subgroups.":[229],"These":[230],"results":[231],"suggest":[232],"that":[233],"provides":[235],"benefit":[237],"broad":[240],"range":[241],"Clinical":[246],"trial":[247],"information:":[248],"NCT02589717.RECIST":[249],"v1.1":[250],"characteristic.":[254],"n":[255],"ORR,":[256],"%":[257,260,262,264,267],"95%":[258,265],"CI,":[259,266],"CR,":[261],"DCR,":[263],"All":[268],"15":[270],"9,":[271],"23":[272],"3":[273,313],"49":[274],"40,":[275,315],"59":[276],"CrCl,":[277],"6":[281],"0":[282,285,303],"0,":[283,301],"46":[284,293],"50":[286,306],"12,":[287],"88":[288],"19":[290,302,310],"21":[291,323],"6,":[292],"5":[294,367],"63":[295],"38,":[296,326],"84":[297],"27":[299],"4":[300,381],"14,":[305],"\u2265":[307],"60":[308],"62":[309],"10,":[311,334],"31":[312],"53":[314],"66":[316],"only":[319],"102":[320],"13":[321],"7,":[322],"2":[324,354,364,386],"48":[325],"58":[327,337],"histologya":[331],"12":[332],"33":[333],"65":[335],"8":[336],"28,":[338],"85":[339],"Median":[340],"follow-up":[341],"(N":[342],"=":[343],"214):":[344],"2.3":[345],"mo":[346],"(range":[347],"1.6-3.4).a":[348],"1":[349,361,376,392],"PR":[350,365],"among":[353,366],"an":[357],"adenocarcinoma":[358],"component":[359],"CR":[362],"+":[363],"\u201cother\u201d":[370,394],"subtype.":[371],"No":[372],"pt":[377],"sarcomatoid":[379],"squamous":[384,389],"components;":[385],"SD.":[397]},"counts_by_year":[{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-09-27T00:00:00"}